English translation of content medically reviewed in Romanian by Dr. Claudiu Ruscu, intensive care physician (anaesthesia & intensive care)· Romanian text reviewed 20 September 2026
1250RON
Consultation included if you go ahead · otherwise 200 RON
or message us on WhatsAppCertified doctors · Payment at the clinic
The high dose of NAD+ — our premium longevity protocol. Given slowly, after a medical assessment.
Available at the clinic or at home in Bucharest & Ilfov. See all prices.

The indication is decided at the medical assessment, based on your history, test results and goals. The doctor tells you whether this protocol is right for you.
The full list of contraindications is discussed during the consultation.
NAD+ 250 mg slow drip
The dose is adjusted individually, based on the medical consultation. Every substance is pharmaceutical grade, given intravenously for higher bioavailability.
We assess your health and decide whether this protocol is right for you.
You are seated comfortably. The IV cannula is placed and monitoring begins.
The infusion is given slowly, under medical monitoring, for optimal tolerability.
Afterwards, we check how you are feeling. You can leave straight away.
The 250 mg dose is given very slowly — usually over 2-3 hours — precisely so that it is well tolerated. The doctor adjusts the rate continuously; if you feel any discomfort, the drip is slowed down. It is a protocol where patience makes the difference to comfort.
The higher the dose of NAD+, the slower the rate needs to be to avoid unpleasant sensations (chest pressure, nausea, flushing). The 250 mg dose is the premium protocol and is given over a longer period, with monitoring, for the best tolerance.
You may feel warmth or slight pressure if the rate goes up — which is why it runs slowly. Most people sit back and relax for the whole drip. You are monitored throughout, and any discomfort is dealt with straight away by adjusting the rate.
Yes: pregnancy and breastfeeding, severe kidney failure, known allergies to any of the components and severe active infections. All of these are checked at the medical consultation before the drip — the protocol is not given without an assessment.
1250 RON, medical consultation included. Available at the clinic or at home in Bucharest and Ilfov, with the price published transparently.
English translation of answers medically reviewed in Romanian. They do not replace a consultation — indications and contraindications are decided individually, at the medical assessment.
The studies below support the statements on mechanism, pharmacokinetics and safety on this page. They do not support a guaranteed therapeutic outcome — each one is followed by its limitation.
[1] Grant R, Berg J, Mestayer R, et al. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD. Front Aging Neurosci. 2019.
randomised trial · sample: 11 · PMID 31572171
Limitation: Only 8 healthy men aged 30–55 (3 in the control group), a single infusion followed for 8 hours, with no measurement of NAD+ inside the cells and no clinical outcome. The infusion was given at a wellness centre, and two authors have links to NAD+ Research Inc. and Springfield Wellness Center.
[2] Reyna K, Heinzen G, Patel N, et al. Intravenous infusion of nicotinamide adenine dinucleotide (NAD(+)) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting. Front Aging. 2026.
observational study · sample: 14 · PMID 41704678
Limitation: Only 6 people received NAD+, with no randomisation, and the data were extracted retrospectively from records. All authors were employees of the chain that sold the infusions (Restore Hyperwellness). The dose was 500 mg on 4 consecutive days, double Synerva's 250 mg protocol.
[3] Covarrubias AJ, Perrone R, Grozio A, et al. NAD(+) metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021.
narrative review · PMID 33353981
Limitation: A narrative review, with no systematic method. The causal link between falling NAD+ and age-related diseases, and their “reversal”, comes mainly from rodent models. The review states explicitly that it is not known whether restoring NAD+ in humans is safe and beneficial. One author is a co-founder of Napa Therapeutics.
[4] Massudi H, Grant R, Braidy N, et al. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS One. 2012.
observational study · sample: 49 · PMID 22848760
Limitation: A cross-sectional study on pelvic skin from patients operated on for another reason: a single tissue, with no follow-up over time. The abstract shows only a correlation, not a magnitude such as “at 50 compared with 20”. Two authors were directors of the company NADLife.
[5] Zhu XH, Lu M, Lee BY, et al. In vivo NAD assay reveals the intracellular NAD contents and redox state in healthy human brain and their age dependences. Proc Natl Acad Sci U S A. 2015.
observational study · PMID 25730862
Limitation: A cross-sectional study, of the brain only, using a method that was new at the time of publication. The group of volunteers is small, and the exact number is not given in the abstract. It shows an association with age, not that NAD+ given from outside changes anything.
[6] Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD(+) in healthy middle-aged and older adults. Nat Commun. 2018.
randomised trial · sample: 30 · PMID 29599478
Limitation: An oral precursor, not intravenous NAD+. 30 participants enrolled, only 6 weeks per arm. NAD+ was measured in blood cells, not in muscle or brain, and the physiological effects (blood pressure, arterial stiffness) were only explored.
[7] Gallagher C, Emmanuel OO NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Res Rev. 2026.
systematic review · PMID 41655607
Limitation: A review without a meta-analysis, written by two authors, the first of whom runs a management company for an aesthetic clinic. It also includes 80 rodent studies. The search stops in October 2025. For intravenous NAD+, the conclusion is an absence of studies, not proof that it does not work.
Indications, studies and frequently asked questions: the complete guide to NAD+ 250 mg.
We use necessary cookies and, only with your consent, analytics and marketing cookies.We use cookies to improve your experience on this site. Strictly necessary cookies are always on. You can also accept analytics and marketing cookies, or decline them. Details